Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 11/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | CDK9 | P50750 | 5/20 | 0.42 |
| ▸ | CDK7 | P50613 | 10/20 | 0.35 |
| ▸ | CCNH | P51946 | 10/20 | 0.35 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15598335 | 0.89 | CCNK (0.43) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL15565491 | 0.84 | CCNK (0.43) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL24311837 | 0.74 | MAP3K14 (0.47) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25599273 | 0.72 | CCNK (0.60) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25600700 | 0.68 | CCNK (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL29364271 | 0.67 | MAP3K14 (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25029293 | 0.67 | MAP3K14 (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL25600703 | 0.66 | CLK1 (0.52) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL28817250 | 0.66 | CCNK (0.48) | CCNKCDK12CCNT1CCNE1CDK2 | |
| SCHEMBL6039779 | 0.66 | JUN (0.51) | CDK2HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725462-B2 | Pyridopyrimidine derivatives as protein kinase inhibitors | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725462-B2 | Pyridopyrimidine derivatives as protein kinase inhibitors | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-2882746-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2882746-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2882746-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023385-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014023385-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SYK, LYN, IRAK1 | CCNK 345/4885CDK12 315/4885CCNT1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.